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ABSTRACT
The human papillomavirus (HPV) life cycle is tightly linked to differentiation of the infected epithelial cell, suggesting a sophis-
ticated interplay between host cell metabolism and virus replication. Previously, we demonstrated in differentiated keratino-
cytes in vitro and in vivo that HPV type 16 (HPV16) infection caused increased levels of the cellular SR splicing factors (SRSFs)
SRSF1 (ASF/SF2), SRSF2 (SC35), and SRSF3 (SRp20). Moreover, the viral E2 transcription and replication factor that is ex-
pressed at high levels in differentiating keratinocytes could bind and control activity of the SRSF1 gene promoter. Here, we show
that the E2 proteins of HPV16 and HPV31 control the expression of SRSFs 1, 2, and 3 in a differentiation-dependent manner. E2
has the greatest transactivation effect on expression of SRSF3. Small interfering RNA depletion experiments in two different
models of the HPV16 life cycle (W12E and NIKS16) and one model of the HPV31 life cycle (CIN612-9E) revealed that only SRSF3
contributed significantly to regulation of late events in the virus life cycle. Increased levels of SRSF3 are required for L1 mRNA
and capsid protein expression. Capsid protein expression was regulated specifically by SRSF3 and appeared independent of other
SRSFs. Taken together, these data suggest a significant role of the HPV E2 protein in regulating late events in the HPV life cycle
through transcriptional regulation of SRSF3 expression.
IMPORTANCE
Human papillomavirus replication is accomplished in concert with differentiation of the infected epithelium. Virus capsid pro-
tein expression is confined to the upper epithelial layers so as to avoid immune detection. In this study, we demonstrate that the
viral E2 transcription factor activates the promoter of the cellular SRSF3 RNA processing factor. SRSF3 is required for expres-
sion of the E4^L1mRNA and so controls expression of the HPV L1 capsid protein. Thus, we reveal a new dimension of virus-host
interaction crucial for production of infectious virus. SRSF proteins are known drug targets. Therefore, this study provides an
excellent basis for developing strategies to regulate capsid protein production in the infected epithelium and the production of
new virions.
Human papillomaviruses (HPVs) infect epithelia causing be-nign lesions or warts. For the so-called “high-risk” (HR)
HPVs such as HPV type 16 (HPV16), the most prevalent HPV,
persistent infection causes cervical and other anogenital lesions
and head and neck lesions that may progress to cancer (1). Al-
though prophylactic vaccines against the most prevalent HR-
HPVs are available, therapies are still required to treat infected
individuals who are not vaccinated. A more comprehensive un-
derstanding of the HR-HPV replication cycle could help in the
development of novel therapeutic approaches.
The HPV16 life cycle is tightly linked to differentiation of the
epithelium the virus infects (2). Initial infection is within basal
epithelial cells where the episomal viral genome is maintained at
around 50 to 100 nuclear copies (3). Differentiation of infected
epithelial cells leads to activation of early and then late gene ex-
pression (4). The viral replication and transcription factor, E2, is
expressed at greatest levels in the middle to upper layers of the
epithelium (5, 6) where, together with the viral DNA helicase, E1,
it facilitates vegetative viral DNA replication, leading to produc-
tion of thousands of viral genome copies (7). The viral late pro-
teins, including the capsid proteins L1 and L2, are synthesized in
the uppermost granular layer of the epithelium to encapsidate the
newly replicated genomes (4). This spatial restriction of produc-
tion of the highly immunogenic capsid proteins is important since
it avoids triggering an immune response as a result of low immune
surveillance in the upper epithelial layers.
Expression of virus capsid proteins is known to be controlled
not only at the level of transcription initiation but also at various
posttranscriptional levels, including polyadenylation, alternative
splicing, nuclear export, mRNA stability, and translation (2,
8–12). Notably, at least 13 mRNAs are produced late in the virus
life cycle that contain open reading frames encoding the capsid
proteins (10). Seven mRNAs contain the L1 but not the L2 open
reading frame, and six mRNAs contain both L1 and L2 open read-
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ing frames. Alternative splicing regulates the proportions of the
various late mRNAs encoding the capsid proteins (12). In partic-
ular, viral capsid protein L1 is thought to be encoded by an E4^L1
mRNA produced by splicing from a splice donor site at the end of
the E4 open reading frame to the splice acceptor site at the start of
the L1 coding region, while the L2 capsid protein is encoded by a
readthrough L2L1 RNA (10).
Constitutive splicing is the process whereby introns are re-
moved from pre-mRNAs and exons are spliced together to form a
protein-coding mRNA. Alternative splicing is a mechanism used
by mammalian and viral genomes to maximize coding potential
(13, 14). A gene is transcribed to give a single primary transcript,
but from this precursor RNA (pre-mRNA) different mature
mRNA isoforms are produced by differential inclusion or exclu-
sion of exons and introns. Each alternatively spliced mRNA iso-
form can encode a different protein. Alternative splicing is directly
regulated by the following two classes of proteins, SR proteins
(serine-arginine-rich splicing factors [SRSFs]) and heterogenous
ribonucleoproteins (hnRNPs) (15). SR proteins can bind to ex-
onic sequence enhancers (ESEs) to stimulate recognition of adja-
cent splice sites by the splicing machinery, while hnRNPs
recognize exonic splicing silencers (ESSs) to repress splice site uti-
lization (16). Therefore, the combinations of cis-acting ESEs and
ESSs in open reading frames, together with the relative concentra-
tions of trans-acting SR and hnRNP proteins that can access these
sites, determine the ultimate mRNA isoforms produced from a
single gene.
Aside from splicing, SR proteins can potentially regulate other
processes that control protein production from an mRNA, in-
cluding transcription elongation, polyadenylation, nonsense-me-
diated decay, nuclear export mRNA stability, and translation (17).
Nine classical SR proteins have been described: SRSF1 to SRSF9.
Previous data have demonstrated the importance of a number of
these proteins in production of HPV mRNAs (18). SRSF1 (SF2/
ASF), SRSF3 (SRp20), and SRSF9 (SRp30c) have been shown to
bind viral mRNAs in the E4 open reading frame (19–22). SRSF2
(SC35) and SRSF3 have been shown to control production of the
viral E6 and E7 oncoprotein mRNAs (19, 23). Previous studies
that have examined SR protein regulation of viral RNA splicing in
tumor cells transiently expressing subgenomic reporter constructs
have demonstrated that SRSF1 controls expression of early and
late viral mRNAs (20, 22), while SRSF3 can regulate BPV1 and
HPV16 early and late gene expression (19). SRSF9 can also control
HPV16 late gene expression (21).
Previously, we demonstrated in vitro and in vivo that HPV16
infection upregulated the expression of a specific subset of SR
proteins in differentiating epithelial cells, SRSF1, SRSF2, and
SRSF3, (24). Subsequently, we showed that the viral transcription
factor E2 activated the SRSF1 promoter via its transactivation do-
main (25). We demonstrate here that HPV16 E2 also specifically
transactivates the promoters of SRSF2 and SRSF3. We have ex-
tended the work to show that HPV31 E2 can also transcriptionally
control SR protein expression in an epithelial differentiation-stage
specific manner. Small interfering RNA (siRNA) depletion exper-
iments were used to determine which HPV-regulated SR pro-
tein(s) was important for HPV16 late mRNA and capsid protein
production. The data revealed that SRSF3 depletion resulted in
significantly reduced levels of L1 protein, suggesting that E2-reg-
ulated SRSF3 is required for capsid protein expression. SRSF3 was
required for expression of the viral E4^L1 spliced mRNA but ap-
peared to repress expression of the L2L1 unspliced readthrough
RNA. Taken together, these data indicate that the E2 protein links
the viral replication cycle to epithelial differentiation via SRSF3, a
key cellular regulator of HR-HPV gene expression.
MATERIALS AND METHODS
Cell lines. W12E cells are nontumor cervical epithelial cells (clone 20863
[26]) that, if maintained at low passage (17), contain 50 to 100 nuclear
episomal copies of the HPV16 genome. NIKS16 cells are normal immor-
talized keratinocytes (NIKS) stably transfected with the HPV16 genome.
Clone 2L maintains episomal HPV16 genomes (27). CIN612-9E cells are
cervical keratinocytes containing episomal HPV31 genomes (28). All
three lines form tissues in raft culture that mimic a low-grade cervical
lesion. W12E, NIKS, NIKS16, and CIN612-9E cells were cultured in E-
medium and differentiated as described (2 105 cells per 10-cm plate) on
mitomycin C-treated J2 3T3 mouse fibroblasts (10, 26). Cells were differ-
entiated by growing to high density in the presence of 1.88 mM Ca2 as
previously described (26). The 3T3 cells were grown in Dulbecco modified
Eagle medium (DMEM) with 10% donor calf serum. Prior to harvesting
for RNA or protein preparation, 3T3 cells were removed by trypsinization
and cells layers washed twice with phosphate-buffered saline (PBS). U2OS
osteosarcoma cells and U2OS clones stably expressing HPV16 E2
(U2OSA4 and U2OSB1) were cultured in DMEM with 10% fetal calf
serum. All cells were maintained under humidified 5% CO2 and 95% air at
37°C.
Cell transfection and siRNA depletion. Cells were seeded at 2 105
per 10-cm dish and grown for 4 days on mitomycin C-treated J2 3T3
mouse fibroblasts as described above. At day 4, fibroblasts were removed
by brief trypsinization. Keratinocytes were washed twice with PBS and
transfected with plasmids using Lipofectamine 3000 according to the
manufacturer’s protocol. At 8 h after transfection, freshly prepared mito-
mycin C-treated J2 3T3 mouse fibroblasts were added back to the kerati-
nocyte cultures in fresh E-medium. After 72 h, the cells were harvested
into 400 l of protein loading buffer (125 mM Tris [pH 6.8], 4% sodium
dodecyl sulfate [SDS], 20% glycerol, 10% mercaptoethanol, 0.006% bro-
mophenol blue, and fresh protein inhibitor cocktail [Roche, United King-
dom]). Lysates were passed through a 21-gauge needle 15 times and then
sonicated in a Sonibath for 3 30 s. Cells were seeded at 2 105 per well
in a six-well plate 24 h prior to transfection in antibiotic-free medium.
siRNA (10 nM) and Lipofectamine RNAiMAX (Invitrogen) were diluted
in Opti-MEM serum-free medium (Invitrogen). Cells were transfected
for 48 h according to the manufacturer’s protocol. siGENOME SMART
pools (consisting of four siRNAs designed to minimize off-target effects)
specific for each of the SRSFs tested were purchased from Dharmacon.
Transfection efficiencies as calculated by cotransfection with siGLO
(Dharmacon) or a green fluorescent protein (GFP) expression plasmid
were between 70 and 80%.
Cloning the SRSF3 expression vector. pEGFPSRp20 was a gift from
R. Sandri-Goldin. The insert fragment from pEGFPSRp20 was cleaved out
using BamHI/EcoRI restriction digestion. The fragment was then inserted
using the same sites into pcDNA3.1 to give plasmid pcDNA3.1SRSF3.
Cloning the SRSF promoters. SRSF promoter regions were amplified
from HeLa cell DNA. For SRSF1pr, the forward primer was 5=-GAT
CCTCGAGGTTACGGTTCTCACATCCATTTTGC-3=, and the reverse
primer was 5=-GTGCAAGCTTCTCCCGCGGCCCCTCCAAAATG-3=
(amplifying nucleotides [nt] 886 to 143 relative to the transcription
initiation site at1). For SRSF2pr, the forward primer was 5=-GGGTGG
TACCGTCAGCTCTCCTCGGGGCGAAG-3=, and the reverse primer
was 5=-GTACAAGCTTTCTCAGGCAGTTGCCTTCCGCG-3= (amplify-
ing nt985 to96 relative to the transcription initiation site at1). For
SRSF3pr, the forward primer was 5=-GATCGGTACCGCGGCTCTGTCT
TCGTAAGGG-3=, and the reverse primer was 5=-GTGCAAGCTTCTCT
CACTCACCCGGCGTCC-3= (amplifying nt720 to81 relative to the
transcription initiation site at1). For SRSF7pr, the forward primer was
5=-CATCCTCGAGACCAACTAGGCCTGCTTTCC-3=, and the reverse
Klymenko et al.
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primer was 5=-GTGCAAGCTTAAACAGCCAAGAAACGACGC-3= (am-
plifying nt1036 to69) relative to the transcription initiation site at
1). Nucleotides in boldface italics indicate the XhoI or HindIII restriction
enzyme sites that were used for cloning. A 4-bp overhang was added to the
end of each primer sequence to facilitate restriction enzyme cleavage. PCR
was performed with high-fidelity Platinum Taq polymerase (Invitrogen).
Single amplicons were obtained with the correct theoretical length. PCR
products were ligated into pGL3 basic vector (Promega) and transformed
into supercompetent Escherichia coli DH5 (Invitrogen). Insert se-
quences of clones obtained were confirmed by DNA sequencing.
Transcription assays. U2OS and U2OS clones A4 and B1 cells that
stably express HPV16-E2 (29) were seeded in 10-mm-well plates at 105
cells per well without antibiotics 24 h prior to transfection. Transfections
were carried out using Lipofectamine 2000 (Invitrogen). An EGFP expres-
sion vector (pMAXEGFP) was used as a transfection efficiency control
using. Protein was extracted 48 to 72 h posttransfection as follows. Cells
were washed twice in ice-cold PBS after the removal of the culture me-
dium. NP-40 lysis buffer (0.5% NP-40, 150 mM NaCl, 50 mM Tris HCl
[pH 8]) with protease (Roche Diagnostics) and phosphatase (Roche Di-
agnostics) inhibitors was added to the cells, and the cells scraped into the
buffer on ice. The lysed cells were transferred to a 1.5-ml Eppendorf tube
and incubated on ice for 30 min with periodic vortexing. The extracts were
centrifuged at 10,000  g for 10 min, and the supernatant was subse-
quently stored at80°C. A luciferase assay system (Promega) and a Glo-
Max–Multi detection system luminometer were used to detect luciferase
activity according to the manufacturer’s instructions. Samples were nor-
malized by protein concentration. At least three independent experiments
were performed.
Cloning the HPV31 genome E2:I73L mutant. The I73L mutation in
the HPV31 genome was created using the QuikChange XL site-directed
mutagenesis kit (Agilent) using the plasmid pLit-HPV31 as the template
and the primers 5=-GCCAAAGCCTTACAAGCTcTTGAACTACAAATG
ATGTTGG-3= and 5=-CCAACATCATTTGTAGTTCAAgAGCTTGTAA
GGCTTTGGC-3= according to the manufacturer’s directions. Primary
human foreskin keratinocytes were transfected with recircularized
HPV31 genomes and expanded after drug selection as previously de-
scribed (30).
Western blotting. Cells were scraped into protein-loading buffer (125
mM Tris [pH 6.8], 4% SDS, 20% glycerol, 10% mercaptoethanol, and
0.006% bromophenol blue with fresh protein inhibitor cocktail [Roche,
United Kingdom]). Lysates were passed through a 21-gauge needle 15
times and then sonicated in a Sonibath for 3 30 s. Subsequently, 10 g
of protein (or 5, 10, or 20 g where indicated) was resolved by polyacryl-
amide gel electrophoresis (PAGE) using Novex precast 4 to 12% gradient
gels (Invitrogen) and then transferred to nitrocellulose membrane using
an i-Blotter (Invitrogen). The membrane was preincubated for 1 h at
room temperature with 5% dried milk powder in PBS– 0.1% Tween (PBS-
T), before overnight incubation at 4°C with diluted primary antibody in
PBS-T–1% dried milk powder. The following antibodies were used:
SRSF1 (clone 96; Invitrogen, catalog no. 32-4500) at 1:1,000, SRSF2 (BD
Pharmingen, catalog no. 556363) at 1:250, SRSF3 (clone 7B4; Invitrogen,
catalog no. 33-4200) at 1:250, SRSF7 (clone 98, a gift from James Stevenin,
IGBMC, Strasbourg, France) at 1:100, GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase; clone 6CS; Biodesign International, catalog no.
H86504M) at 1:5,000, Involucrin (Sigma, catalog no. 19018) at 1:1,000,
HPV16 E2 (clone TVG261; Abcam, catalog no. ab17185) at 1:250, and
HPV L1 (clone K1H8; Dako, catalog no. M3528). Mab104 (used neat)
detects a phospho-epitope on SRSFs 1 to 6 (an ATCC hybridoma super-
natant). Because SRSFs1 and 2 have similar apparent molecular masses on
SDS-PAGE, as well as probing with Mab104, we also probed blots with
specific monoclonal antibodies against these SR proteins as above. Horse-
radish peroxidase-conjugated secondary antibodies (Pierce-ECL) were
diluted 1:2,000 in PBS-T and incubated for 1 h. Blots were developed
using Pierce enhanced chemiluminescence (ECL) kit and exposed to
Kodak X-Omat film. Blots were quantified by scanning at 300 dpi and
image analysis using ImageJ.
Immunohistochemistry.Archival paraffin-embedded cervical biopsy
samples were obtained with ethical permission (Glasgow Royal Infirmary,
permit RN04PC003). Diagnosis was made by a gynecological pathologist.
HPV presence was confirmed by PCR. Immunohistochemistry was car-
ried out by the University of Glasgow Veterinary Diagnostic Services.
SRSF3 antibody (clone 7B4; Invitrogen, catalog no. 33-4200) was used at
a dilution of 1:100.
RNA extraction. Cells were scraped into TRIzol reagent (Invitrogen)
and total RNA was extracted according to the manufacturer’s protocol.
Polyadenylated RNA was isolated using an oligo(dT)-based mRNA ex-
traction kit (Oligotex; Qiagen) according to the manufacturer’s instruc-
tions. DNA was removed from all RNAs using the Promega RQ1 DNase
kit according to the manufacturer’s instructions. DNase-treated RNA was
reverse transcribed using the Superscript III kit (Invitrogen) according to
the protocol provided.
PCR. cDNA was amplified using 200 nM primers, 200M dNTPs, 1.5
mM MgCl2 and 2 units Taq polymerase (Invitrogen). The primers for
E4^L1 amplification were E4 forward (nt 3518 to 3540; 5=-GTTGTTGCA
CAGAGACTCAGTGG-3=) matched with L1 reverse (nt 6918 to 6997;
5=-GACAAGCAATTGCCTGGGTTAC-3=). The primers for L2L1 ampli-
fication were L2 forward (nt 5465 to 5475; 5-GTATCAGGTCCT-
GATATACCC-3=) matched with L1 reverse B (nt 5690 to 5669; 5=-TACT
GGGACAGGAGGCAAGTAG-3=), GAPDH forward (5=-TCCACCACC
CTGTTGCTGTA-3=), and GAPDH reverse (5=-ACCACAGTCCATGCC
ATCAC-3=). PCR products were separated on a 6% acrylamide gel and
poststained with ethidium bromide.
qPCR. cDNA was amplified using an Applied Biosystems 7500 qPCR
machine. The Stratagene Brilliant qPCR Mastermix was used for quanti-
tative PCRS (qPCRs). cDNA (100 ng) was amplified in each reaction
in triplicate, and three different experiments were performed. Reaction
mixtures (25 l) contained 1Mastermix (Stratagene), 900 nM concen-
trations of primers, 100 nM concentrations of probe, and 300 nM con-
centrations of reference dye (Stratagene) as follows: E4 forward primer (nt
3594 to 3615; 5=-CTGTAATAGTAACACTACACCC-3=), E4^L1 probe
(nt 3620 to 3631 and nt 5637 to 5656; 5=-TACATTTAAAAGTGTCTCTT
TGGCTGCCTAG-3=), L2 forward primer (nt 5547 to 5569; 5=-CAATTA
TTGCTGATGCAGGTGAC-3=), L2L1 probe (nt 5600 to 5622; 5=-CGAA
AACGACGTAAACGTTTACC-3=), and L1 reverse (nt 5690 to 5669; 5=-T
ACTGGGACAGGAGGCAAGTAG-3=). The amplification protocol was
95°C for 15 s, followed by 50°C for 60 s for 40 cycles. Expression was
quantified by determining the CT relative to the GAPDH values.
RESULTS
HPV E2 regulates the promoters of the genes encoding SRSF1,
-2, and -3. Using cell line models of epithelial differentiation and
HPV infection and backed up by data from virus-infected patient
tissue, we and others demonstrated that SRSF1 (SF2/ASF), SRSF2
(SC35), and SRSF3 (SRp20) are specifically upregulated in HPV-
infected, differentiated epithelial cells (24, 25, 31, 32). For SRSF1,
we showed previously that HPV16 E2 controlled the promoter of
the SRSF1 gene by interacting within a region from nt565 to nt
363 with respect to the transcription initiation site (this was
originally cited as nt689 to nt482 in our previous paper [25]
according to the numbering of a previously sequenced version of
the SRSF1 promoter). Transcription activation was through the
E2 transactivation domain (25). E2 was only able to transactivate
the SRSF1 promoter in the A4 clone of the osteosarcoma cell line
U2OS that stably expresses low E2 levels (Fig. 1A) (25, 29). We
proposed previously that E2 may begin to transrepress the SRSF1
promoter at higher concentrations, as it has been shown to do for
the BPV4 long control region promoter (25). To examine whether
E2 also controlled expression of the genes encoding the other two
HPV16 Late Gene Expression Is Controlled by SRSF3
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SR proteins, SRSF2 and SRSF3, both of which are upregulated in
HPV-infected cells, we cloned their gene promoters into luciferase
expression (pGL3-luciferase) vectors for transcription analysis.
The SRSF1 promoter (previously assayed in a chloramphenicol
acetyltransferase [CAT] construct) was cloned in the same vector
in order to use as a known E2-regulated control. The promoter for
SRSF7 (9G8) was also cloned and analyzed in order to compare an
SRSF family member that we have shown is not upregulated dur-
ing differentiation of HPV-infected cervical epithelial cells (24). A
non-SR protein promoter control, the hTERT promoter whose
expression is downregulated by HPV E2 (33), and a pGL3 empty
vector with no promoter sequence was also used. U2OS subclones
A4 and B1, stably express different amounts of HPV16 E2 protein:
A4 expresses low levels, and B1 expresses high levels (Fig. 1A) (25,
29). Transient transfections of the different luciferase expression
vectors were performed in U2OS, U2OSA4, and U2OSB1 cells. An
EGFP expression vector was cotransfected in each transfection
experiment in order to normalize transfection efficiency. Figure
1B shows quantification of luciferase expression from the different
promoters indicated on the x axis. Control transfections of the
promoterless pGL3 vector showed very low luciferase activity
(pGL-3 empty). hTERT promoter activity was low in all the ex-
periments. This is due to U2OS cells displaying low telomerase
activity (34). Despite the low levels of reporter gene expression
some decrease was detected in the U2OSB1 cell line that expresses
higher levels of E2 as expected (33). Similar to what we reported
previously, the SRSF1 promoter was transactivated by E2 protein
in the U2OSA4 cell clone, which expresses low levels of HPV16 E2.
However, the higher levels of E2 expressed by the U2OSB1 cell
clone did not upregulate the SRSF1 promoter, confirming our
previous data (25). The SRSF2 promoter also showed a small but
statistically significant upregulation by HPV16 E2 protein. Under
the control of the SRSF2 promoter, luciferase activity was in-
creased 1.35-fold in U2OSA4 cells and 1.24-fold in U2OSB1 cells
(P  0.05). However, a greater increase in activity of the SRSF3
promoter than that observed for SRSF1 and SRSF2 in the presence
of E2 was observed. The basal activity of the SRSF3 promoter in
U2OS cells was lower than either the SRSF1 or 2 promoters and
HPV E2 protein gave a greater transactivation response, showing a
larger absolute difference in the fold change in luciferase activity.
The luciferase activity was increased 2.93-fold in U2OSA4 cells
and 2.69-fold in U2OSB1 cells (P 0.001) (Fig. 1B). In contrast to
the repressive effect seen on SRSF1 promoter activity, high levels
of E2 expression did not abrogate the transactivation of the SRSF3
promoter. The SRSF7 promoter is not controlled by HPV16 in-
fection (24) and showed no statistically significant change in ac-
tivity in the presence of E2 demonstrating that the E2-mediated
upregulation of SRSF1, -2, and -3 is specific (Fig. 1B).
Differentiation of HPV31-positive keratinocytes increases
SRSF1, -2, and -3 levels. W12 cells are cervical epithelial cells de-
rived from a patient with an HPV16-positive low grade cervical
lesion (35). Cells of the non-tumor subclone W12E (clone 20863),
when maintained at low passage (P 	 17), contain around 50 to
100 episomal copies of the HPV16 genome (26, 35). W12E cells
can be induced to differentiate to keratinocytes that express mark-
ers of terminal differentiation (36), viral late mRNAs and late
proteins (10) by culturing to high density in the presence of 1.88
mM Ca2. Previously, we showed that a subset of SRSF proteins,
including SRSF1, -2, and -3, were upregulated upon differentia-
tion of W12E cells (24). To determine whether control of SRSF
expression during epithelial differentiation was associated with
other HR-HPV infections, we examined SR protein levels in
HPV31-infected CIN612-9E cervical epithelial cells (28). CIN612-9E
cells were established from an HPV31-infected low-grade cervical
lesion and contain episomal HPV31 viral genome copies.
CIN612-9E cells can also be induced to differentiate in culture
using the same protocol as for W12 cells (by culturing to high
density in the presence of 1.88 mM Ca2) to express viral late
mRNAs and synthesize virions (37, 38). Monoclonal antibodies
against SRSF1, SRSF3, and SRSF7 perform well in Western blot-
ting. However, to detect the remainder of the SR proteins, we used
Mab104, which detects a phospho-epitope on most of the classical
SR proteins (SRSF1, -2, 4, -5, and -6). Therefore, in Fig. 2A, de-
tection of SRSF1 is shown both with Mab104 and the SRSF1-
specific antibody Mab96. Semiquantitative Western blot analysis
of protein titrations (5, 10, and 20 g) showed that the levels of
SRSF1, -2, and -3 were higher in differentiated compared to un-
differentiated HPV31-positive cells (Fig. 2A), similar to what was
found in W12E cells (24). In contrast to W12E cells, CIN612-9E
cells expressed SRSF4 (SRp75), whose levels also increased upon
differentiation. Levels of SRSF5 (SRp40) and SRSF6 (SRp55) in-
creased slightly upon differentiation. The levels of SRSF7 did not
change significantly. Cell differentiation was revealed by detection
of increased levels of the epithelial differentiation marker involu-
crin in the differentiated keratinocytes (Fig. 2A).
The E2 transactivation domain is required for control of
SRSF1, -2, and -3 levels. The data support the hypothesis that
HR-HPV E2, which is expressed at highest levels in differentiating
HPV-infected epithelial cells (5, 6), controls expression of SR pro-
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FIG 1 HPV16 E2 transactivates the promoters of SRSFs 1 to 3. (A) Western
blot analysis of levels of E2 protein in two clones of U2OS cells (U2OSA4 and
U2OSB1) stably transfected with an HPV16 E2 expression vector (29). U2OSv
cells were transfected with empty vector. GAPDH is shown as a control for
protein loading levels. (B) Luciferase transcription assays reveal E2 transacti-
vation of the SRSF1, -2, and -3 promoters. A graph is shown of the luciferase
activity in U2OSv (dark gray bars), U2OSA4 (light gray bars), and U2OSB1
(mid gray bars) cells transiently transfected with luciferase expression vectors
under the control of the promoters, shown on the x axis, or the promoterless
vector, pGL3, as a negative control. The means and standard deviations from
three separate experiments are shown. Asterisks show statistically significant
changes (P values) determined using a Student t test (two-tailed). *, P 0.05;
***, P 0.001.
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teins. To test this directly, we compared levels of SR proteins in
normal foreskin keratinocytes (NFKs) stably transfected with
wild-type HPV genomes or with genomes containing an inactivat-
ing point mutation in the transactivation domain of E2. HPV16
genomes containing such a mutant cannot be maintained epi-
somally in keratinocytes (39). However, keratinocytes containing
HPV31 genomes with this mutation are available (mutant E2:
I73L) (30). If E2 transactivated the SRSF1-3 promoters, there
would be reduced levels of the proteins in these keratinocytes.
Western blot quantification indeed revealed decreased levels of
SRSF1, -2, and -3 in the keratinocytes expressing the mutant E2
protein compared to keratinocytes expressing wild-type E2
(E2wt), but there was no change in the levels of SRSF7, as ex-
pected, since it is not regulated by E2 (Fig. 2B). There were similar
viral genome copy numbers in E2wt and E2:IL-73 NFKs (data not
shown). Figure 2C shows the levels of E2 protein in each NFK line.
Compared to the levels of GAPDH, there were similar levels of E2
protein expressed in E2wt compared to E2:IL-73 cells (Fig. 2C,
lanes 3 and 4). The NFK E2wt and E2:IL-73 protein extracts used
in Fig. 2B were prepared from differentiated NFK clones because
both expressed involucrin, a marker of epithelial differentiation
(Fig. 2C, lanes 3 and 4). Both E2wt and E2:IL-73 NFKs clearly
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FIG 2 The transactivation domain of HPV31 E2 is required for the control of SRSF1, -2, and -3 and the production of L1 protein. (A) SRSF levels are increased
in differentiated HPV31-infected CIN612-9E cells. Semiquantitative Western blot analysis was performed to determine the levels of SR proteins in undifferen-
tiated (U) and differentiated (D) CIN612-9E cells. Protein extracts (5, 10, or 20g) were loaded as indicated above the blots. SRSF1, -3, and -7 were detected with
specific monoclonal antibodies, as indicated on the right-hand sides of the blots. SRSF1, -2, -4, -5, and -6 were detected with Mab104, which detects phospho-
epitopes of all of the classical SR proteins except SRSF9. Involucrin was detected as a control for differentiated epithelial cells. Involucrin is detected in the
undifferentiated cells due to ca. 20% of these having undergone differentiation. GAPDH was detected as a protein loading control. A single gel was blotted and
probed with antibodies against SRSF1 and involucrin. The same samples were electrophoresed on identical gels for probing with GAPDH/SRSF7 or with
Mab104/SRSF3. This experiment was repeated three times, with very similar results from each Western blot. (B) Keratinocytes containing a transactivation-
negative E2 point mutant HPV31 genome have reduced levels of SRSF1, -2, and -3. Western blot analysis of SRSF1, -2, and -3 levels in normal human foreskin
keratinocytes (NFKs) stably transfected with wild-type E2 (E2wt) or point mutant E2:I73L HPV31 genomes (E2:IL-73). SRSF7 was detected as a control for an
SR protein whose levels are not changed upon epithelial differentiation or significantly transactivated by HPV16E2. The levels of L1 protein in the two lines are
also shown. The experiment was carried out three times using two different clones of each E2-expressing keratinocyte line. Very similar results were obtained in
each experiment. (C) Western blot analysis of levels of E2 protein and differentiation status of NFKs stably transfected with wild-type E2 (E2wt) or point mutant
E2:I73L HPV31 genomes (E2:IL-73). As a marker of differentiation, the levels of involucrin are shown in undifferentiated (U) and differentiated (D) CIN6129E
keratinocytes for comparison. The experiment was carried out twice using two different clones of each E2-expressing keratinocyte line. Very similar results were
obtained in each experiment. (D) Quantification of levels of the SR proteins shown in panel B. The graph shows the means and standard deviations from three
separate experiments. Values were calculated relative to the GAPDH levels. Very similar data were obtained with two different clones of each keratinocyte line.
(E) Western blot quantification of levels of L1 protein in differentiated NFKs stably maintaining wild-type HPV31 and in NFKs stably maintaining point mutant
E2:I73L HPV31 genomes. The graph shows the means and standard deviations from three separate experiments. Values were calculated relative to the GAPDH
levels. P values were calculated using a Student t test.
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expressed more involucrin than undifferentiated HPV31-positive
CIN6129E cells (Fig. 2C, lanes 2), and the levels were almost as
high as fully differentiated CIN6129E cells (Fig. 2C, lanes 1). The
levels of SRSF1 in the E2:I73L-expressing cells were 52%
 3.2%
of the wild type, while the levels of SRSF2 and -3 were 31%
 6.5%
and 29% 
 5.0% of the wild type, respectively (Fig. 2D). These
data indicate that E2 transactivates the SRSF gene promoters to
control expression of SRSF1, -2, and -3 proteins in infected epi-
thelial cells. E2:I73L mutant HPV31 genomes express ca. 80% less
late mRNA than wild-type genomes (30), but whether this leads to
reduced L1 protein expression has not been tested. In accordance
with the reported change in late mRNA production, Western blot-
ting revealed that there was a reduction of around 75% in L1
protein expression from E2:I73L genomes compared to E2 wild-
type genomes (P 0.01) (Fig. 2E). Our data suggest that HR-HPV
E2 upregulates the expression of SR proteins 1, 2, and 3 in infected,
differentiated keratinocytes.
SRSF3 controls expressionof theHPV16L1 capsidprotein in
differentiated keratinocytes. E2-mediated upregulation of cellu-
lar SR proteins 1, 2, and 3 in differentiated infected epithelial cells
could indicate that increased levels of these RNA processing pro-
teins are required for completion of the viral replication cycle.
Therefore, we next determined which of the differentiation stage-
specific controlled SR proteins controlled HPV capsid protein ex-
pression during the HPV life cycle in differentiating keratinocytes.
For these experiments, we used both the HPV16-infected W12E
life cycle model we had used previously (24) and a second model
of the HPV16 infectious life cycle (NIKS16) to corroborate
our data with W12 cells. NIKS16 cells are normal immortalized
foreskin keratinocytes (NIKS) stably transfected with episomal
HPV16 genomes (27). If used at low passage, NIKS16 clone 2L
stably maintains episomal genomes. Like W12E and CIN612 9E
cells, they can differentiate in monolayer culture and display a
CIN1-like phenotype in organotypic raft culture (27). Differenti-
ation of W12E, NIKS16, and the parental NIKS cells can be in-
duced by culturing in 1.88 mM Ca2 to high density (10, 26). At
the end of the differentiation protocol between 75 and 85% of
NIKS or NIKS16 cells expressed the differentiation marker invo-
lucrin similar to that observed with W12E cells (10). Using
Mab104 that simultaneously detects SRSFs1, -2, -4, -5, and -6 and
antibody 7B4 that detects specifically SRSF3, semiquantitative
Western blotting of 5, 10, and 20 g of HPV-negative NIKS pro-
tein extracts revealed very little change in levels of SR proteins
upon differentiation, a finding similar to what we observed previ-
ously using HPV-negative HaCaT cells (25) (Fig. 3A). However,
semiquantitative Western blotting of 5, 10, or 20 g of HPV16-
positive NIKS16 protein extract revealed a pattern of change
in SRSF expression between undifferentiated and differenti-
ated NIKS16 cells similar to that observed for W12E (24) and
CIN612-9E cells (Fig. 2A). Figure 3B shows that levels of SRSFs1,
-2, and -3 were higher in differentiated NIK16 cells. The levels of
SRSF4 and -6 also appeared to increase slightly, while the SRSF5
and -7 levels (SRSF7 was detected with specific monoclonal anti-
body clone 98) did not change. Quantification of changes in
SRSF3 levels between undifferentiated and differentiated HPV-
negative NIKS cells revealed a reduction of 30% upon differenti-
ation (Fig. 3C). In contrast, SRSF3 levels increased 4-fold upon
differentiation of HPV16-positive NIKS16 cells similar to the in-
crease in SRSF3 levels we quantified in W12 cells previously (24)
(Fig. 3D). Immunohistochemistry staining of normal cervical ep-
ithelium revealed staining in the basal layer cells and some in the
suprabasal layers (Fig. 3E). Immunohistochemistry staining of a
representative low-grade cervical lesion revealed that whereas
more cells in the basal epithelial layers stained positive for SRSF3
compared to cells in the upper layers, the intensity of staining of
cells in the middle to upper layers was strong, indicating high
levels of SRSF3 expression (Fig. 3F).
Having demonstrated that NIKS16 cells control expression of
SRSFs1, -2, and -3 in a similar manner to W12E and CIN612-9E
cells (24), these SR proteins were depleted using siRNA in NIKS16
keratinocytes. SRSFs 5 and 7 were also depleted as controls for SR
proteins that are not regulated by E2 or HPV infection. Figure 4A
shows that levels of each of the SR proteins were significantly
reduced by their respective siRNAs. SRSF1, -2, and -5 were de-
tected with Mab104 (top panel) that detects most of the classical
SR proteins. The second panel from the top shows detection of
SRSF1 using the specific antibody Mab96. A second panel showing
SRSF1 and -2 detected together is included as the third panel down
from the top because SRSF2 depletion is not clearly seen in the top
panel. The bottom two panels show SRSF3 detected by specific
antibody 7B4 and SRSF7 detected by specific antibody clone 98.
Levels of L1 protein were assessed as a marker of late events in the
virus life cycle in the SRSF-depleted cells by Western blotting with
an HPV L1 antibody. L1 was expressed in differentiated (Fig. 4B,
lane 2) but not in undifferentiated (Fig. 4B, lane 1) NIKS16 cells,
as expected from data from raft cultures of this line (27). Differ-
entiation was assessed by increased expression of the epithelial
differentiation marker involucrin (Fig. 4B, compare lanes 1 and
2). There was no significant change in levels of L1 protein in dif-
ferentiated NIKS16 cells when either SRSF1, -2, -5, or -7 were
depleted. However, depletion of SRSF3 (Fig. 4B, lane 5) caused a
significant decrease in L1 protein expression. Quantification of
three separate experiments showed that loss of SRSF3 caused a
53% 
11% (P  0.05) decrease in L1 protein expression in dif-
ferentiated NIKS16 cells (Fig. 4C).
Next, we confirmed the SRSF3 regulation of L1 expression in
the W12E model of the HPV16 life cycle. SRSF1 was used as a
control SR protein since this did not significantly affect the levels
of HPV16 L1 protein in NIKS16 cells (Fig. 4B and C). SRSF1 and
SRSF3 were successfully depleted using specific siRNAs in undif-
ferentiated (W12U) and differentiated (W12D) W12E cells (Fig.
5A). Involucrin expression was higher in the differentiated cell
population as expected (Fig. 5A, lanes 4 to 6). No L1 protein ex-
pression was detected in undifferentiated W12 cells, but high lev-
els of L1 protein were detected in differentiated W12E cells (Fig.
5A, lane 4). Depletion of SRSF1 had a small reduction effect in L1
protein expression in the differentiated cells (Fig. 5A, lane 5) but,
consistent with the data using NIKS16 cells, SRSF3 depletion re-
duced the L1 protein levels significantly (Fig. 5A, lane 6). Quanti-
fication of the data from three separate experiments showed that
L1 protein levels were reduced by 55% 
11% (P  0.05) in dif-
ferentiated W12E cells (Fig. 5B).
If SRSF3 depletion in differentiated NIKS16 cells results in the loss
of L1 expression, then the overexpression of SFSF3 in undifferenti-
ated NIKS16 cells might activate L1 expression. To test this, we trans-
fected undifferentiated NIKS16 cells with an expression construct for
SRSF3 (pcDNA3.1SRSF3). Cells were maintained at low cell density
in medium with low calcium concentrations over the course of the
experiment to minimize differentiation (26). At 72 h after transfec-
tion, the cells were harvested, and the protein lysates were prepared.
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Western blot analysis revealed that cells transfected with vector alone
did not express L1 protein (Fig. 5C, lane 2). In contrast, cells trans-
fected with the SRSF3 expression construct showed some L1 expres-
sion (Fig. 5C, lane 3) but not to the level detected in fully differenti-
ated NIKS16 cells (Fig. 5C, lane 1). The transfected NIKS16 cells had
not been induced to differentiate because levels of involucrin differ-
entiation marker were low in the transfected cells (Fig. 5C, lanes 2 and
3) compared to the fully differentiated NIKS16 cell control (Fig. 5C,
lane 1). Taken together, the data reveal that SRSF3 is a key regulator of
HPV16 L1 protein levels.
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FIG 3 SRSF3 levels increase upon differentiation of HPV16-infected cells (A) SRSF1, -2, and -3 levels do not alter upon differentiation of HPV-negative NIKS
cells. Semiquantitative Western blot analysis of levels of SR proteins in undifferentiated (U) and differentiated (D) NIKS cells. Protein extracts (5, 10, or 20 g)
were loaded as indicated above the blots. SRSF3 was detected with the specific monoclonal antibody 7B4. SRSF1, -2, -4, -5, and -6 were detected with Mab104.
SRSF7 was not tested in this experiment because its levels did not change upon HPV infection (24). Involucrin was detected as a control for differentiation of
epithelial cells. GAPDH was detected as a protein loading control. (B) SRSF1, -2, and -3 levels are increased in differentiated NIKS16 cells. Semiquantitative
Western blot analysis of the levels of SR proteins in undifferentiated (U) and differentiated (D) NIKS16 cells was performed. Protein extracts (5, 10, or 20g) were
loaded as indicated above the blots. SRSF3 and -7 were detected with specific monoclonal antibodies. SRSF1, -2, -4, -5, and -6 were detected with Mab104.
Involucrin was detected as a control for differentiated epithelial cells. GAPDH was detected as a protein loading control. The experiments in panels A and B were
carried out at least three times, with very similar results obtained each time. (C) Quantification of SRSF3 levels in undifferentiated (U) and differentiated (D)
HPV-negative NIKS cells. The graph shows the means and standard deviations from three separate experiments. Values were calculated relative to the GAPDH
levels. (D) Quantification of SRSF3 levels in undifferentiated (U) and differentiated (D) NIKS16 cells. The graph shows the means and standard deviations from
five separate experiments. Values were calculated relative to the GAPDH levels. (E) Immunohistochemical staining of a representative normal cervical epithelium
(10 normal lesions were stained) with an antibody against SRSF3. Note that the strongly stained nuclei are present mainly in the lower epithelial layers. (F)
Immunohistochemical staining of a representative low-grade cervical lesion (10 low-grade lesions were stained) with an antibody against SRSF3. Note the
strongly stained nuclei in the middle to upper epithelial layers. The picture in panel E is taken at a lower magnification than that in panel F to show that the staining
pattern is consistent over a wide area of tissue.
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SRSF3 depletion results in loss of the E4^L1 spliced RNA.
SRSF3 can regulate mRNA expression at a number of different
levels (40), and it is known to be a master regulator of alternative
splicing (41). Alternative splicing is a key control mechanism of
HPV gene expression. HPV L1 capsid protein is thought to be
expressed from an E4^L1 spliced transcript (RNA B) but may also
be expressed from an E1^L1 (RNA A) or the bicistronic L2L1
transcript (RNA C) (Fig. 5A) (10, 42). Therefore, we examined
whether the levels of any of these mRNAs were affected by SRSF3
depletion during the HPV16 life cycle. We mock depleted or
siRNA depleted SRSFs 1 and 3 in W12E cells and allowed the cells
to differentiate. siRNA treatment successfully depleted levels of
SRSF1 and -3 (Fig. 5B). We used primer pairs to PCR amplify
across splice junctions E1^L1 and E4^L1 or across the junction of
the open reading frames in the readthrough L2L1 mRNA. E1^L1
proved very difficult to detect, indicating that it is an mRNA pres-
ent at very low levels in HPV16-positive keratinocytes. In viral late
mRNAs, the end of the E4 open reading frame contains a splice
donor site at nt 3632 that allows splicing to the L1 splice acceptor
site at nt 5639. E4^L1 mRNAs were detected readily. Compared to
the effect of SRSF1 depletion, which has only a small effect on L1
protein production, SRSF3 depletion caused a remarkable de-
crease in levels of late mRNA E4^L1 (RNA B) in differentiated
W12E cells (Fig. 5C, lane 6). SRSF1 depletion did not alter pro-
duction of this RNA (Fig. 5C, lane 4). In contrast, depletion of
SRSF1 or SRSF3 appeared to increase the levels of the L2/L1 bicis-
tronic mRNA (RNA C) (Fig. 5C, lower panel, lanes 4 and 6). The
levels of GADPH did not change upon SRSF1 or SRSF3 depletion.
qRT-PCR analysis using previously published probe/primer sets
(43) confirmed that E4^L1 mRNA levels were reduced signifi-
cantly upon SRSF3 depletion in differentiated cells (Fig. 5D),
whereas the bicistronic L2L1 mRNA levels increased when either
SRSF1 (2.0-fold) or SRSF3 (1.7-fold) were depleted (Fig. 5E).
Taken together, these data suggest that SRSF3 can control produc-
tion of L1 capsid protein via enhancing the expression of the
E4^L1 mRNA.
DISCUSSION
Focusing on the paradigm SR protein SRSF1, we demonstrated
previously that E2 bound the SRSF1 promoter and its transactiva-
tion domain was essential for the upregulation of SRSF1 tran-
scription (25). Here, we have shown that E2 transcriptionally ac-
tivates the genes encoding not only SRSF1 but also SRSF2 and -3.
The SRSF3 promoter displayed the highest level of transactivation
in our transcription assays. E2 regulated the SRSF3 promoter in a
dose-dependent manner. This is from the SRSF1 promoter that
we found was activated by low but repressed by high levels of E2
(25; the present study). We do not yet understand how E2 trans-
activates the SRSF promoters because, similar to what we have
found for the SRSF1 promoter (24), the SFSR2 and -3 promoters
do not contain a cognate E2 binding site. In silico analysis of the
proximal promoter sequences of SRSF1, -2, and -3 revealed that
they are each predicted to bind the E2-interacting factors Sp1 and
cEBP (data not shown), but it remains to be tested whether E2
binds and transactivates via these proteins and whether other fac-
tors are also involved. It is even possible that the array of cellular
transcription factors that control each promoter may be different
and mediate different transcriptional responses to E2. SRSF7 was
used in the transcription assays as a control promoter since it is
not regulated by E2, but we did not clone and test E2 control of
other SRSFs. Therefore, we cannot conclusively rule out the pos-
sibility that E2 controls the expression of additional SRSF pro-
teins. However, our data clearly reveal that the cellular SRSF1, -2,
and -3 genes are upregulated by HPV16 E2. This is the first re-
ported cloning of these SRSF promoters.
Semiquantitative Western blotting experiments revealed a
similar profile of changes in SRSF protein levels upon differentia-
tion of HPV16-positive W12E cells (24), NIKS16 cells (Fig. 3A),
and the HPV31-positive CIN612-9E cells. This allowed us to test
the mechanism of E2 control of the SRSF promoters by comparing
levels of the SRSF proteins in normal foreskin keratinocytes stably
transfected with a wild-type HPV31 genome or a genome contain-
ing a single inactivating point mutation in the E2 transactivation
domain (30). There was a significant decrease in expression of
SRSFs 1 to 3 in keratinocytes expressing the point mutant E2.
These data support our hypothesis that HR-HPV E2 controls the
promoters of these SR proteins via its transactivation domain.
SRSF3 levels showed the greatest change, with a 71% decrease
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FIG 4 SRSF3 is required for L1 protein expression. (A) Western blot analysis
of SR protein depletion for the experiment shown in panel B. SRSF1, -3, and -7
were detected with specific antibodies. SRSF1, -2, and -5 were detected with
Mab104. The panel showing SRSF2 depletion was probed with Mab104. Only
the area of the blot showing SRSF2 and SRSF1 bands is shown. SRSF2 is the
upper band. U, undifferentiated NIKS16 cells; D, differentiated NIKS16 cells;
Cntrl, cells transfected with a control siRNA. (B) SRSF3 depletion results in
reduced L1 protein levels. Western blot analysis of L1 protein in differentiated
keratinocytes (D) with the various SR proteins depleted was performed. Un-
differentiated NIKS16 cell extracts (U) were analyzed as a negative control for
L1 protein expression; Cntrl, cells transfected with a control siRNA. Involucrin
was detected as a control for differentiated epithelial cells. GAPDH was de-
tected as a protein loading control. (C) Quantification of levels of L1 protein in
NIKS16 keratinocytes transfected with a control siRNA (cntrl) or siRNAs
against each of the SR proteins shown on the x axis. U, undifferentiated kera-
tinocytes; D, differentiated keratinocytes. The graph shows the means and
standard deviations from three separate experiments. Values were calculated
relative to the GAPDH levels. The P value was calculated using a Student t test.
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detected in cells expressing the mutant E2 compared to wild-type
E2. The reported increased levels of E2 in the middle to upper
layers of HPV-infected epithelia (5, 6) fits well with the increase in
SRSF1, -2, and -3 expression in differentiated compared to undif-
ferentiated W12E cells (24), NIKS16 cells, and CIN612-9E cells
(the present study). It will be of interest to determine whether
other high-risk and low-risk HPV types control SRSFs during the
infectious life cycle. Our data imply that E2 control of SRSF1, -2,
and -3 is likely at the level of transcription initiation. However,
because E2 has been shown to possess some properties of SR pro-
teins (44–46), we cannot discount a direct E2-mediated regulation
of HPV mRNA processing or indeed E2 control of alternatively
spliced isoforms of SR protein mRNAs that are more stimulatory
of L1 splicing.
Also, although E2 is a regulator of SRSFs, we cannot rule out
the possibility that other HPV proteins could be involved in con-
trolling SRSF expression. For example, E6 and E7 may activate
cellular transcription factors and control SRSF levels indirectly in
differentiated keratinocytes (47, 48).
Our data suggest that a specific subset of SR proteins (SRSFs 1
to 3) is regulated by E2, indicating that these proteins may have
important functions during the HPV replicative life cycle. Reason-
ing that increased SR protein expression in differentiated kerati-
nocytes might impact late events in the viral life cycle, we com-
pared the effect of siRNA depletion of each of the E2-regulated
SRSFs 1 to 3 with SRSF5 and -7 (the latter two of which are not
controlled by E2 in the NIKS16 model) on capsid protein expres-
sion. Depletion of SR proteins 2, 5, and 7 had no significant effect
on L1 protein expression. Depletion of SRSF1 caused a modest
reduction in L1 protein expression in NIKS16 and W12 cells as
predicted by a previous study (20). However, SRSF3 depletion
caused a major reduction in L1 protein expression in the differen-
tiated NIKS16 cells. SRSF3 control of L1 expression was con-
firmed in a second HPV16 life cycle model using W12E cells. Con-
versely, the overexpression of SRSF3 in undifferentiated NIKS16
cells resulted in some induction of L1 protein expression. We were
unable to repeat the experiment in the W12 cell model due to
problems inhibiting differentiation in these cells during the course
of the overexpression experiment. Although further work is re-
quired to determine whether the effect of SRSF3 on L1 induction
in undifferentiated epithelial cells is at the level of mRNA process-
ing, our data indicate that SRSF3 is a key regulator of viral capsid
protein expression.
Although we did not carry out SR protein depletion experi-
ments in CIN612-9E cells, we observed a significant decrease in
capsid protein production in human keratinocytes maintaining
E2:I73L mutant genomes, with a concomitant 50% reduction in
SRSF3 expression, compared to cells containing wild-type HPV31
genomes. This does not prove that SRSF proteins control L1 pro-
tein production in HPV31-positive keratinocytes, but it is correl-
ative with the observations in the HPV16-positive lines. The4-
fold level of L1 protein depletion we observed (Fig. 2D) agrees
with the 80% reduction observed previously in L1 mRNA produc-
tion in foreskin keratinocytes expressing the HPV31 E2:I73L mu-
tant genome (30). The greater effect of the E2 inactivating point
mutation on L1 protein expression compared to SRSF3 depletion
could be due to incomplete knock down of SRSF3 in our experi-
ments. However, it may be due to other effects of E2 on HPV or
cellular gene expression. E2 appears to be required for induction
of HPV late mRNA expression by inhibiting the viral early poly-
adenylation signal through interaction with CPSF30 (11). Al-
though in our study an HPV31 E2 transactivation domain point
mutant was all that was required to reduce virus capsid protein
expression, in the study by Johannson et al. both the E2 transac-
tivation domain and the hinge region were required for control of
the L1 and L2 mRNA levels (11). This suggests that there at least
two E2-regulated mechanisms for controlling the viral late gene
expression, and these are not mutually exclusive. Apart from these
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important mechanisms, E2 can bind other RNA processing fac-
tors, including the SR proteins SRSF1, -2, and -7 (49) and could
modulate their splicing activities as well as or instead of control-
ling transcription of SRSF genes. Moreover, E2 possesses SR pro-
tein-like properties itself since it can bind RNA and affect splicing
in vitro (44, 45). Importantly, a recent study revealed that in U2OS
cells E2 can control human gene expression by inducing alterna-
tive splice isoforms of mRNAs that encode proteins involved in
cancer formation and cell motility (46). Therefore, it is possible
that E2 could control late mRNA expression directly. A complex
combination of different E2-regulated mechanisms may be es-
sential in differentiation stage-specific control of HPV gene
expression.
Several previous studies have reported the effects of SR pro-
teins on HPV gene expression. These reports have delineated ESEs
and ESSs and their interacting proteins on viral RNAs. SRSF1
binds a downstream ESE in the E4 open reading frame to control
the viral splice acceptor site 3258 (20). SRSF2 controls HPV16
oncoprotein expression by regulating mRNA stability (23). SRSF3
also controls HPV16 oncoprotein expression (19), but to a lesser
extent than SRSF2 (23). SRSF9 can activate the E4 splice donor
3632 while inhibiting splice acceptor 3358 at the 5= end of the E4
open reading frame (21). Of interest, another splicing control el-
ement in the E4 coding region (50) binds SRSF3 (19). Knocking
down SRSF3 in U2OS osteosarcoma cells increased levels of both
L1 and L2 mRNAs while mutating the SRSF3 binding site in-
creased L1 mRNA production 2-fold (19). In contrast to that
study, we found that SRSF3 depletion in undifferentiated epithe-
lial cells did not induce L1 protein expression (Fig. 3E). Moreover,
our data indicate that SRSF3 is required for the L1-encoding
E4^L1 mRNA and L1 protein expression in differentiating kerati-
nocytes. Although some of the effects we have observed are rather
modest, the differences in our data compared to the previous
studies can be attributed to our use of differentiating, HPV-in-
fected nontumor epithelial cells (three different model systems)
that better mimic the natural HPV life cycle. Further, wild-type
HPV genomes are present in NIKS16 and W12E and CIN612-9E
cells. In contrast, in the previous studies, subgenomic constructs
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with deletions in important cis-acting elements (e.g., the late neg-
ative regulatory region [51]) controlling gene expression were
used (20, 21, 50). In our HPV-infected lines, viral transcription is
driven from the natural viral promoters (10, 38) which are rela-
tively weakly active. Expression of HPV late mRNAs from the
subgenomic constructs is under the control of the strong CMV
promoter. Of importance, RNA polymerase II elongation rate,
determined by promoter strength, is a major determinant of the
use of weak over strong splice sites regardless of ESE/ESS activity
(52, 53). Finally, the exact levels of SR proteins in cells are known
to be vital to their function in splicing (54), meaning the effects on
HPV late gene expression of the SRSF levels found in undifferen-
tiated tumor cells may be different from their effects in differen-
tiated keratinocytes.
However, it is important to consider that because we have an-
alyzed HPV gene expression, together with keratinocyte differen-
tiation upon SRSF knockdown, some of the effects we observed
could be an indirect result of SRSF-mediated control of other
cellular factors or of epithelial differentiation itself. For example,
in Fig. 6A we observed an increase in expression of the epithelial
differentiation marker involucrin upon SRSF3 depletion, imply-
ing that SRSF3 may repress involucrin expression upon epithelial
differentiation. Further work will be required to determine
whether SRSF3 is controlling HPV late gene expression directly or
whether it does so through other cellular pathways.
Immunohistochemical staining of HPV16-infected low-grade
cervical lesions has revealed a distinct pattern of SRSF3 expression
(24; the present study). SRSF3 is expressed in the majority of basal
epithelial cells. Although fewer cells in the upper epithelial layers
express SRSF3, those that do express the protein contain very
densely stained nuclei (Fig. 3F). We propose that these cells are
HPV infected and support late events in the viral replication cycle,
including E2-mediated control of SRSF3 expression. In prepara-
tion for capsid protein production, viral late mRNAs may be pro-
duced in epithelial cells below the granular layer (8), colocating
with high levels of E2 and SRSF3. SRSF3 appears to be required for
expression of the E4^L1 late mRNA that encodes the L1 capsid
protein. Conversely, SRSF1 and SRSF3 negatively regulate pro-
duction of the L2L1 read through RNA that likely encodes L2. This
could be one regulatory mechanism that ensures high levels of L1
and low levels of L2 protein production to provide the correct
ratio of L1 to L2 protein for capsid formation. SRSF3 can cross-
regulate SRSF2, SRSF5, and SRSF7 and has been proposed as a
master regulator of RNA splicing (41). The cooperative activity of
SR proteins imposes positive and negative combinatorial control
on splicing (54). Therefore, in the future it will be important to
examine the effect of siRNA depletion of combinations of E2-
controlled SR proteins on the HPV gene expression program.
In conclusion, if HPV-regulated SR proteins are key to com-
pletion of the viral replication cycle, they may represent a useful
target for antiviral therapy. Small-molecule inhibitors of SR pro-
tein kinases that modulate the functions of SR proteins are avail-
able. Since they have been shown to be effective in inhibiting rep-
lication of HIV, hepatitis C virus, and Sindbis virus (14), they may
also be effective against HPV replication. However, it will also be
important also to understand any potential effects of these thera-
pies on the switch from the viral replicative cycle to persistent or
latent infection that underlies tumor progression. Nevertheless,
such targets may prove effective for future therapeutic study.
ACKNOWLEDGMENTS
This study was funded by Wellcome Trust grant Wtd004098. The funders
had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
We thank Margaret Stanley (University of Cambridge) and Paul Lam-
bert and Denis Lee (University of Wisconsin) for provision of the W12
cells. We are grateful to Craig Meyers (Penn State University) for the gift
of CIN612-9E cells and to John Doorbar (University of Cambridge) for
the NIKS16 cells. Iain Morgan (Virginia Commonwealth University)
kindly provided the U2OS cells lines transfected with HPV16 E2. We are
grateful to Lou Laimins (Northwestern University, Chicago, IL) for agree-
ing to provide the protein extracts of the wild-type and E2:I73L mutant
HPV31-transfected keratinocytes. We declare no conflicts of interest.
FUNDING INFORMATION
This work was funded by Wellcome Trust grant Wtd004098 to S. V.
Graham. The funders had no role in study design, data collection and
interpretation, or the decision to submit the work for publication.
REFERENCES
1. zurHausenH. 2009. Papillomaviruses in the causation of human cancers:
a brief historical account. Virology 384:260 –265. http://dx.doi.org/10
.1016/j.virol.2008.11.046.
2. Graham SV. 2010. Human papillomavirus: gene expression, regulation
and prospects for novel diagnostic methods and antiviral therapies. Future
Microbiol 5:1493–1505. http://dx.doi.org/10.2217/fmb.10.107.
3. Groves IJ, Coleman N. 2015. Pathogenesis of human papillomavirus-
associated mucosal disease. J Pathol 235:527–538. http://dx.doi.org/10
.1002/path.4496.
4. Doorbar J. 2005. The papillomavirus life cycle. J Clin Virol 32S:S7–S15.
5. Xue Y, Bellanger S, Zhang W, Lim D, Low J, Lunny D, Thierry F. 2010.
HPV16 E2 is an immediate early marker of viral infection, preceding E7
expression in precursor structures of cervical carcinoma. Cancer Res 70:
5316 –5325. http://dx.doi.org/10.1158/1538-7445.AM10-5316.
6. Coupe VM, Gonzalez-Barreiro L, Gutierrez-Berzal J, Melian-Boveda
AL, Lopez-Rodriguez O, Alba-Dominguez J, Alba-Losada J. 2012. Tran-
scriptional analysis of human papillomavirus type 16 in histological sec-
tions of cervical dysplasia by in situ hybridization. J Clin Pathol 65:164 –
170. http://dx.doi.org/10.1136/jclinpath-2011-200330.
7. McBride AA. 2013. The papillomavirus E2 proteins. Virology 445:57–79.
http://dx.doi.org/10.1016/j.virol.2013.06.006.
8. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker
TR. 1992. Human papillomavirus type 16 and 18 gene expression in cer-
vical neoplasia. Hum Pathol 23:117–128. http://dx.doi.org/10.1016/0046
-8177(92)90232-R.
9. Zhou J, Lui WJ, Peng SW, Sun XY, Frazer IH. 1999. Papillomavirus
capsid protein expression levels depends on the match between codon
usage and tRNA availability. J Virol 73:4972– 4982.
10. Milligan SG, Veerapraditsin T, Ahamat B, Mole S, Graham SV. 2007.
Analysis of novel human papillomavirus type 16 late mRNAs in differen-
tiated W12 cervical epithelial cells. Virology 360:172–181. http://dx.doi
.org/10.1016/j.virol.2006.10.012.
11. Johannson C, Somberg M, Li X, Winquist EB, Fay J, Ryan F, Pim D,
Banks L, Schwartz S. 2012. HPV-16 E2 contributes to induction of
HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J
31:3212–3227. http://dx.doi.org/10.1038/emboj.2012.147.
12. Johannson C, Schwartz S. 2013. Regulation of human papillomavirus
gene expression by splicing and polyadenylation. Nat Rev Microbiol 11:
239 –251. http://dx.doi.org/10.1038/nrmicro2984.
13. Singh RK, Cooper TA. 2012. Pre-mRNA splicing in disease and thera-
peutics. Trends Mol Med 18:472– 482. http://dx.doi.org/10.1016/j
.molmed.2012.06.006.
14. Hernandez-Lopez HR, Graham SV. 2012. Alternative splicing in tumour
viruses: a therapeutic target? Biochem J 445:145–156. http://dx.doi.org/10
.1042/BJ20120413.
15. Busch A, Hertel KJ. 2012. Evolution of SR proteins and hnRNP splicing
regulatory factors. Wiley Interdiscip Rev RNA 3:1–12. http://dx.doi.org
/10.1002/wrna.100.
16. Roca X, Krainer AR, Eperon IC. 2013. Pick one, but be quick: 5= splice
sites and the problem of too many choices. Genes Dev 27:129 –144. http:
//dx.doi.org/10.1101/gad.209759.112.
HPV16 Late Gene Expression Is Controlled by SRSF3
May 2016 Volume 90 Number 10 jvi.asm.org 5057Journal of Virology
 o
n
 O
ctober 26, 2017 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
17. Long JC, Caceres JF. 2009. The SR protein family of splicing factors:
master regulators of gene expression. Biochem J 417:15–27. http://dx.doi
.org/10.1042/BJ20081501.
18. Kajitani N, Schwartz S. 2015. RNA binding proteins that control human
papillomavirus gene expression. Biomolecules 5:758 –774. http://dx.doi
.org/10.3390/biom5020758.
19. Jia R, Liu X, Tao M, Kruhlak M, Guo M, Meyers C, Baker CC, Zheng
ZM. 2009. Control of the papillomavirus early-to-late switch by differen-
tially expressed SRp20. J Virol 83:167–180. http://dx.doi.org/10.1128/JVI
.01719-08.
20. Somberg M, Schwartz S. 2010. Multiple ASF/SF2 sites in the human
papillomavirus type 16 (HPV-16) E4-coding region promote splicing to
the most commonly used 3=-splice site on the HPV-16 genome. J Virol
84:8219 – 8230. http://dx.doi.org/10.1128/JVI.00462-10.
21. Somberg M, Li X, Johannson C, Orru B, Chang R, Rush M, Fay J, Ryan
F, Schwartz S. 2011. Serine/arginine-rich protein 30c activates human
papillomavirus type 16 L1 mRNA expression via a bimodal mechanism. J
Gen Virol 92:2411–2421. http://dx.doi.org/10.1099/vir.0.033183-0.
22. Li X, Johansson C, Cardoso Palacios C, Mossberg A, Dhanjal S, Bergvall
M, Schwartz S. 2013. Eight nucleotide substitutions inhibit splicing to
HPV-16 3=-splice site SA3358 and reduce the efficiency by which HPV-16
increases the life span of primary human keratinocytes. PLoS One
8:e72776. http://dx.doi.org/10.1371/journal.pone.0072776.
23. McFarlane M, MacDonald AI, Stevenson A, Graham SV. 2015. Human
papillomavirus 16 oncoprotein expression is controlled by the cellular
splicing factor SRSF2 (SC35). J Virol 89:5276 –5287. http://dx.doi.org/10
.1128/JVI.03434-14.
24. Mole S, McFarlane M, Chuen-Im T, Milligan SG, Millan D, Graham
SV. 2009. RNA splicing factors regulated by HPV16 during cervical tu-
mour progression. J Pathol 219:383–391. http://dx.doi.org/10.1002/path
.2608.
25. Mole S, Milligan SG, Graham SV. 2009. Human papillomavirus type 16
E2 protein transcriptionally activates the promoter of a key cellular splic-
ing factor, SF2/ASF. J Virol 83:357–367. http://dx.doi.org/10.1128/JVI
.01414-08.
26. Jeon S, Allen-Hoffman BL, Lambert PF. 1995. Integration of human
papillomavirus type 16 into the human genome correlates with a selective
growth advantage of cells. J Virol 69:2989 –2997.
27. Weschler EI, Wang Q, Roberts I, Pagliarulo E, Jackson D, Untersperger
C, Coleman N, Griffin H, Doorbar J. 2012. Reconstruction of human
papillomavirus type 16-mediated early-stage neoplasia implicated E6/E7
deregulation and the loss of contact inhibition in neoplastic progression. J
Virol 86:6358 – 6364. http://dx.doi.org/10.1128/JVI.07069-11.
28. Hummel M, Hudson JB, Laimins LA. 1992. Differentiation-induced and
constitutive transcription of human papillomavirus type 31b in cell lines
containing viral episomes. J Virol 66:6070 – 6080.
29. Taylor ER, Boner W, Dornan ES, Corr EM, Morgan IM. 2003. UVB
irradiation reduces the half life and transactivation potential of the human
papillomavirus 16 E2 proteins. Oncogene 22:4469 – 4477. http://dx.doi
.org/10.1038/sj.onc.1206746.
30. Stubenrauch F, Colbert AME, Laimins LA. 1998. Transactivation by the
E2 protein of oncogenic human papillomavirus type 31 is not essential for
early and late viral functions. J Virol 72:8115– 8123.
31. McPhillips MG, Veerapraditsin T, Cumming SA, Karali D, Milligan SG,
Boner W, Morgan IM, Graham SV. 2004. SF2/ASF binds the human
papillomavirus type 16 late RNA control element and is regulated during
epithelial differentiation. J Virol 78:10598 –10605. http://dx.doi.org/10
.1128/JVI.78.19.10598-10605.2004.
32. Fay J, Kelehan P, Lambkin H, Schwartz S. 2009. Increased expression of
cellular RNA-binding proteins in HPV-induced neoplasia and cervical
cancer. J Med Virol 81:897–907. http://dx.doi.org/10.1002/jmv.21406.
33. Lee D, Kim H-Z, Jeong KW, Shim YS, Horikawa I, Barrett JC, Choe J.
2002. Human papillomavirus E2 down-regulates the human telomerase
reverse transcriptase promoter. J Biol Chem 277:27748 –27756. http://dx
.doi.org/10.1074/jbc.M203706200.
34. Frolkis M, Fischer MB, Wang Z, Lebkowski JS, Chiu C-P, Majumdar
AS. 2003. Dendritic cells reconstituted with human telomerase gene in-
duce potent cytotoxic T-cell response against different types of tumors.
Cancer Gene Ther 10:239 –249. http://dx.doi.org/10.1038/sj.cgt.7700563.
35. Stanley MA, Browne HM, Appelby M, Minson AC. 1989. Properties of
a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer
43:672– 676. http://dx.doi.org/10.1002/ijc.2910430422.
36. Chuen-Im T, Zhang J, Milligan SG, McPhillips MG, Graham SV. 2008.
The alternative splicing factor hnRNP A1 is up-regulated during virus-
infected epithelial cell differentiation and binds the human papillomavi-
rus type 16 late regulatory element. Virus Res 131:189 –198. http://dx.doi
.org/10.1016/j.virusres.2007.09.006.
37. Hummel M, Lim HB, Laimins LA. 1995. Human papillomavirus type
31b late gene expression is regulated through protein kinase C-mediated
changes in RNA processing. J Virol 69:3381–3388.
38. Ozbun MA, Meyers C. 1997. Characterisation of late gene transcripts
expressed during vegetative replication of human papillomavirus type
31b. J Virol 71:5161–5172.
39. Gauson EJ, Donaldson MM, Dornan ES, Wang X, Bristol M, Bodily JM,
Morgan IM. 2015. Evidence supporting a role for TopBP1 and Brd4 in the
initiation but not continuation of human papillomavirus 16 E1/E2-
mediated DNA replication. J Virol 89:4980 – 4990. http://dx.doi.org/10
.1128/JVI.00335-15.
40. Corbo C, Orru S, Salvatore F. 2013. SRp20: An overview of its role in
human disease. Biochem Biophys Res Commun 436:1–5. http://dx.doi
.org/10.1016/j.bbrc.2013.05.027.
41. Anko M-L, Muller-McNicoll M, Brandi H, Curk T, Gorup C, Henry I,
Ule J, Neugebauer KM. 2012. The RNA-binding landscapes of two SR
proteins reveal unique functions and binding to diverse RNA classes. Ge-
nome Biol 13:R17. http://dx.doi.org/10.1186/gb-2012-13-3-r17.
42. Wang X, Meyers C, Wang H, Chow LT, Zheng ZM. 2011. Construction
of a full transcription map of human papillomavirus type 18 during pro-
ductive viral infection. J Virol 85:8080 – 8092. http://dx.doi.org/10.1128
/JVI.00670-11.
43. Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissman L, Pawlita M.
2010. Diagnosing cervical cancer and high grade precursors by HPV16
transcription patterns. Cancer Res 70:249 –256. http://dx.doi.org/10.1158
/0008-5472.CAN-09-2514.
44. Lai M-C, Teh BH, Tarn W-Y. 1999. A human papillomavirus E2 tran-
scriptional activator. J Biol Chem 274:11832–11841. http://dx.doi.org/10
.1074/jbc.274.17.11832.
45. Bodaghi S, Jia R, Zheng Z. 2009. Human papillomvirus type 16 E2 and E6
are RNA-binding proteins and inhibit in vitro splicing of pre-mRNA with
suboptimal splice sites. Virology 386:32– 43. http://dx.doi.org/10.1016/j
.virol.2008.12.037.
46. Gauson EJ, Windle B, Donaldson MM, Caffarel MM, Dornan ES,
Coleman N, Henderson SC, Wang X, Morgan IM. 2014. Regulation of
human genome expression and RNA splicing by human papillomavirus
E2 protein. Virology 468-470:10 –18. http://dx.doi.org/10.1016/j.virol
.2014.07.022.
47. Roman A, Munger K. 2013. The papillomavirus E7 proteins. Virology
445:138 –168. http://dx.doi.org/10.1016/j.virol.2013.04.013.
48. Vande Pol SB, Klingelhutz AJ. 2013. Papillomavirus E6 proteins. Virol-
ogy 445:115–137. http://dx.doi.org/10.1016/j.virol.2013.04.026.
49. Muller M, Demert C. 2012. The HPV E2-host protein-protein interac-
tions: a complex hijacking of the cellular network. Open Virol J 6:173–189.
http://dx.doi.org/10.2174/1874357901206010173.
50. Rush M, Zhao X, Schwartz S. 2005. A splicing enhancer in the E4 coding
region of human papillomavirus type 16 is required for early mRNA splic-
ing and polyadenylation as well as inhibition of premature late gene ex-
pression. J Virol 79:12002–12015. http://dx.doi.org/10.1128/JVI.79.18
.12002-12015.2005.
51. Graham SV. 2008. Papillomavirus 3=UTR regulatory elements. Front Bio-
sci 13:5646 –5663.
52. Proudfoot N. 2000. Connecting transcription to messenger RNA process-
ing. Trends Biochem Sci 25:290 –293. http://dx.doi.org/10.1016/S0968
-0004(00)01591-7.
53. Moreno NN, Giono LE, Cambindo Botto AE, Munoz MJ, Kornblihtt
AR. 2015. Chromatin, DNA structure and alternative splicing. FEBS Lett
589:3370 –3378. http://dx.doi.org/10.1016/j.febslet.2015.08.002.
54. Bradley T, Cook ME, Blanchette M. 2015. SR proteins control a complex
network of RNA-processing events. RNA 21:75–92. http://dx.doi.org/10
.1261/rna.043893.113.
Klymenko et al.
5058 jvi.asm.org May 2016 Volume 90 Number 10Journal of Virology
 o
n
 O
ctober 26, 2017 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
